Cargando…

Resistance to receptor tyrosine kinase inhibitors in solid tumors: can we improve the cancer fighting strategy by blocking autophagy?

A growing field of evidence suggests the involvement of oncogenic receptor tyrosine kinases (RTKs) in the transformation of malignant cells. Constitutive and abnormal activation of RTKs may occur in tumors either through hyperactivation of mutated RTKs or via functional upregulation by RTK-coding ge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aveic, Sanja, Tonini, Gian Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970224/ https://www.ncbi.nlm.nih.gov/pubmed/27486382 http://dx.doi.org/10.1186/s12935-016-0341-2

Ejemplares similares

Autophagy inhibition improves the cytotoxic effects of receptor tyrosine kinase inhibitors
por: Aveic, Sanja, et al.
Publicado: (2018)

Autophagic flux inhibition enhances cytotoxicity of the receptor tyrosine kinase inhibitor ponatinib
por: Corallo, Diana, et al.
Publicado: (2020)

Combating autophagy is a strategy to increase cytotoxic effects of novel ALK inhibitor entrectinib in neuroblastoma cells
por: Aveic, Sanja, et al.
Publicado: (2015)

Neuroblastoma treatment in the post-genomic era
por: Esposito, Maria Rosaria, et al.
Publicado: (2017)

The zebrafish as a model for studying neuroblastoma
por: Corallo, Diana, et al.
Publicado: (2016)

Desmoplasia in Pancreatic Cancer. Can We Fight It?
por: Merika, E. E., et al.
Publicado: (2012)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

The two facets of receptor tyrosine kinase in cardiovascular calcification—can tyrosine kinase inhibitors benefit cardiovascular system?
por: Masbuchin, Ainun Nizar, et al.
Publicado: (2022)

Wall shear stress during impingement at the building platform can exceed nozzle wall shear stress in microvalve-based bioprinting
por: Nasehi, Ramin, et al.
Publicado: (2023)

Transarterial Chemoembolization Combined With Tyrosine Kinase Inhibitors for Intermediate‐Stage Hepatocellular Carcinoma, What Else Can We Do?
por: Deng, Jun, et al.
Publicado: (2022)

“Can we build it? Yes, we can!” complexities of resource re-deployment to fight pandemic.
por: Elsahn, Ziad, et al.
Publicado: (2021)

Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
por: Huang, Liling, et al.
Publicado: (2020)

Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors
por: Bellantoni, Andrew J., et al.
Publicado: (2021)

More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds
por: Vergoulidou, Maria
Publicado: (2015)

Targeting Tyrosine Kinases and Autophagy in Prostate Cancer
por: Kung, Hsing-Jien
Publicado: (2010)

The VEGFR/PDGFR tyrosine kinase inhibitor, ABT-869, blocks necroptosis by targeting RIPK1 kinase
por: Pierotti, Catia L., et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready?
por: Tabbò, Fabrizio, et al.
Publicado: (2020)

A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways
por: Chen, Celia X.-J., et al.
Publicado: (2023)

Are we winning the fight?
por: Damle, S. G.
Publicado: (2014)

Nilotinib: A Tyrosine Kinase Inhibitor Mediates Resistance to Intracellular Mycobacterium Via Regulating Autophagy
por: Hussain, Tariq, et al.
Publicado: (2019)

Ibrutinib, a Bruton’s tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma
por: Wang, Jin, et al.
Publicado: (2017)

Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia
por: Perrotti, Danilo, et al.
Publicado: (2012)

Altered splicing of ATG16‐L1 mediates acquired resistance to tyrosine kinase inhibitors of EGFR by blocking autophagy in non‐small cell lung cancer
por: Hatat, Anne‐Sophie, et al.
Publicado: (2022)

Latest progress in tyrosine kinase inhibitors
por: Pospelova, Tatiana V., et al.
Publicado: (2014)

Tyrosine kinase inhibitors in sarcoma treatment
por: Kyriazoglou, Anastasios, et al.
Publicado: (2022)

EGFR Tyrosine Kinase Inhibitors Activate Autophagy as a Cytoprotective Response in Human Lung Cancer Cells
por: Han, Weidong, et al.
Publicado: (2011)

Interplay of autophagy, receptor tyrosine kinase signalling and endocytic trafficking
por: Fraser, Jane, et al.
Publicado: (2017)

Regulation of Beclin 1-Mediated Autophagy by Oncogenic Tyrosine Kinases
por: Vega-Rubín-de-Celis, Silvia, et al.
Publicado: (2020)

mTORC1-Inhibition Potentiating Metabolic Block by Tyrosine Kinase Inhibitor Ponatinib in Multiple Myeloma
por: Nazim, Uddin Md., et al.
Publicado: (2022)

An inhibitor of spleen tyrosine kinase suppresses experimental crescentic glomerulonephritis
por: Han, Yingjie, et al.
Publicado: (2018)

Receptor tyrosine kinase inhibitors block proliferation of TGEV mainly through p38 mitogen-activated protein kinase pathways
por: Dong, Wanyu, et al.
Publicado: (2020)

Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?
por: Rendell, Aimee, et al.
Publicado: (2022)

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin
por: Tanaka, Hideki, et al.
Publicado: (2020)

Prognostic value of spleen tyrosine kinase in human solid tumors
por: Ni, Beibei, et al.
Publicado: (2018)

Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer
por: Ragusa, Francesca, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b2ur9p1vu0ek1vafki95e5qtud